AnchorDx, a diagnostics company developing cancer early detection tests, has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectious disease tests, for product development and global commercialization in the cancer screening arena.
AnchorDx and DiaCarta will collaborate to develop and commercialize molecular diagnostic products for the global market. The collaboration will leverage proprietary technologies for DNA methylation and mutation detection developed by each company.
AnchorDx’s DNA methylation test was granted a Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) in July 2021. Meanwhile, AnchorDx is currently conducting a registrational and prospective clinical trial (NCT05643690) for the UriFind PMA application, in which DiaCarta will also participate as one of the clinical testing laboratories.
“Partnering with AnchorDx allows both companies to combine their technical expertise to develop high precision mutation and methylation assays with the needed high sensitivity and specificity to meet the evolving needs for precision diagnostics,” says Adam (Aiguo) Zhang, PhD, CEO and president of DiaCarta.
Through the collaboration with DiaCarta, AnchorDx says it expects to accelerate its early cancer screening programs and develop a robust product pipeline.
“We are committed to bring the best cancer diagnostic products to global market. Toward that goal we are excited to work with the world-leading diagnostics company DiaCarta, to commercialize our leading cancer screening products and co-develop future cancer screening diagnostic tests,” says Jian-Bing Fan, PhD, founder and CEO at AnchorDx.
